Speakers
Steve Gardner
Tim Guilliams
Alan Payne
Panel and Q&A
Although AI technologies have seen a surge in interest in recent years, many of these have been used in life sciences for much longer. But what has the result of these technologies been, and what still needs to change to maximise its utility? We will hear from experts across the life science pipeline as we try to answer this question, and consider the value of AI to our sector.
Tim Guilliams is a tech entrepreneur based in the Cambridge Cluster, UK, with a deep passion for leveraging AI to accelerate treatments for rare diseases.
He is the Co-founder and Chief Executive Officer of Healx Ltd, an AI-powered, patient-centric biotech company that is revolutionising the discovery and development of treatments for rare diseases at scale. Under his leadership, Healx has raised over $100 million and has garnered numerous accolades for its innovative approach.
As CEO of Healx, Tim was honoured with the 'Well Founded Founder/CEO Leadership Award' for his pioneering contributions to HealthTech and patient impact, as well as his commitment to fostering a healthy workplace culture. He has also been recognized in The Sunday Times Maserati 100 list of entrepreneurs, The Telegraph’s Tech 100, and InVivo’s 30 Rising Leaders in the Life Sciences, among other prestigious lists.
In addition to his work at Healx, Tim is the Founding Director of the Cambridge Rare Disease Network (CamRARE), a charity dedicated to improving the lives of those affected by rare diseases.
Tim earned his PhD in Biophysics and Neuroscience from the University of Cambridge’s Department of Chemistry. Before moving to Cambridge, he completed an MEng in Bio- and Chemical Engineering at the University of Brussels
Alan is a Digital and Technology leader with over 30 years’ experience in Healthcare, Health Insurance, Banking and global Capital Markets, specialising in digital innovation across multiple support functions.
He has held executive technology and engineering leadership positions at Aetna International, Nuffield Health, BUPA, Oracle and JPMorganChase, driving product development, transformation and innovation across health and technology.
His current position is Group Product and Engineering Director for the Health, Support & Care division at The Access Group, where he is responsible for the overall vision, direction and delivery of the technology to digitise and integrate health and care.
He holds an Honorary Professorship of AI at the University College London Faculty of Engineering (Intelligent Systems) and has specific research interests in Digital Health, Artificial Intelligence and Entrepreneurship.
Kelly Zalocusky, Ph.D., is Senior Director of Computational Biology, Joint Technical Team Lead of Recurison's 10-year neuroscience collaboration with Roche/Genentech, and Site Lead for Recursion's London Office. Scientifically, her focus is on deploying high-throughput imaging and AI models for novel drug development in neuroscience, and she leads scientific teams focused on applying Recursion's novel platform and approach to the discovery of therapies to radically improve patients’ lives. She is a Neuroscientist by training and received her bachelor's degree from Hendrix College, and Ph.D. from Stanford University.